# A Study of Galcanezumab in Healthy Participants.

> **NCT02836613** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 160 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Galcanezumab

## Key facts

- **NCT ID:** NCT02836613
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2017-02-27
- **Final completion:** 2017-11-09
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836613, "A Study of Galcanezumab in Healthy Participants.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02836613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*